Cite
Kang EY, Millstein J, Popovic G, et al. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Arch. 2021;doi: 10.1007/s00428-021-03232-0.
Kang, E. Y., Millstein, J., Popovic, G., Meagher, N. S., Bolithon, A., Talhouk, A., Chiu, D. S., Anglesio, M. S., Leung, B., Tang, K., Lambie, N., Pavanello, M., Da-Anoy, A., Lambrechts, D., Loverix, L., Olbrecht, S., Bisinotto, C., Garcia-Donas, J., Ruiz-Llorente, S., Yagüe-Fernandez, M., Edwards, R. P., Elishaev, E., Olawaiye, A., Taylor, S., Ataseven, B., du Bois, A., Harter, P., Lester, J., Høgdall, C. K., Armasu, S. M., Huang, Y., Vierkant, R. A., Wang, C., Winham, S. J., Heublein, S., Kommoss, F. K. F., Cramer, D. W., Sasamoto, N., van-Wagensveld, L., Lycke, M., Mateoiu, C., Joseph, J., Pike, M. C., Odunsi, K., Tseng, C. C., Pearce, C. L., Bilic, S., Conrads, T. P., Hartmann, A., Hein, A., Jones, M. E., Leung, Y., Beckmann, M. W., Ruebner, M., Schoemaker, M. J., Terry, K. L., El-Bahrawy, M. A., Coulson, P., Etter, J. L., LaVigne-Mager, K., Andress, J., Grube, M., Fischer, A., Neudeck, N., Robertson, G., Farrell, R., Barlow, E., Quinn, C., Hettiaratchi, A., Casablanca, Y., Erber, R., Stewart, C. J. R., Tan, A., Yu, Y., Boros, J., Brand, A. H., Harnett, P. R., Kennedy, C. J., Nevins, N., Morgan, T., Fasching, P. A., Vergote, I., Swerdlow, A. J., Candido Dos Reis, F. J., Maxwell, G. L., Neuhausen, S. L., Barquin-Garcia, A., Modugno, F., Moysich, K. B., Crowe, P. J., Hirasawa, A., Heitz, F., Karlan, B. Y., Goode, E. L., Sinn, P., Horlings, H. M., Høgdall, E., Sundfeldt, K., Kommoss, S., Staebler, A., Wu, A. H., Cohen, P. A., DeFazio, A., Lee, C. H., Steed, H., Le, N. D., Gayther, S. A., Lawrenson, K., Pharoah, P. D. P., Konecny, G., Cook, L. S., Ramus, S. J., Kelemen, L. E., Köbel, M., Roberts, J., Banerjee, A., & McGee, S. (2021). MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv : an international journal of pathology, . https://doi.org/10.1007/s00428-021-03232-0
Kang, Eun Young, et al. "MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma." Virchows Archiv : an international journal of pathology vol. (2021). doi: https://doi.org/10.1007/s00428-021-03232-0
Kang EY, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Da-Anoy A, Lambrechts D, Loverix L, Olbrecht S, Bisinotto C, Garcia-Donas J, Ruiz-Llorente S, Yagüe-Fernandez M, Edwards RP, Elishaev E, Olawaiye A, Taylor S, Ataseven B, du Bois A, Harter P, Lester J, Høgdall CK, Armasu SM, Huang Y, Vierkant RA, Wang C, Winham SJ, Heublein S, Kommoss FKF, Cramer DW, Sasamoto N, van-Wagensveld L, Lycke M, Mateoiu C, Joseph J, Pike MC, Odunsi K, Tseng CC, Pearce CL, Bilic S, Conrads TP, Hartmann A, Hein A, Jones ME, Leung Y, Beckmann MW, Ruebner M, Schoemaker MJ, Terry KL, El-Bahrawy MA, Coulson P, Etter JL, LaVigne-Mager K, Andress J, Grube M, Fischer A, Neudeck N, Robertson G, Farrell R, Barlow E, Quinn C, Hettiaratchi A, Casablanca Y, Erber R, Stewart CJR, Tan A, Yu Y, Boros J, Brand AH, Harnett PR, Kennedy CJ, Nevins N, Morgan T, Fasching PA, Vergote I, Swerdlow AJ, Candido Dos Reis FJ, Maxwell GL, Neuhausen SL, Barquin-Garcia A, Modugno F, Moysich KB, Crowe PJ, Hirasawa A, Heitz F, Karlan BY, Goode EL, Sinn P, Horlings HM, Høgdall E, Sundfeldt K, Kommoss S, Staebler A, Wu AH, Cohen PA, DeFazio A, Lee CH, Steed H, Le ND, Gayther SA, Lawrenson K, Pharoah PDP, Konecny G, Cook LS, Ramus SJ, Kelemen LE, Köbel M, Roberts J, Banerjee A, McGee S. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Arch. 2021 Nov 15; doi: 10.1007/s00428-021-03232-0. Epub 2021 Nov 15. PMID: 34782936.
Copy
Download .nbib
